ANTONIOLI, ELISABETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.247
EU - Europa 3.170
AS - Asia 1.585
SA - Sud America 185
AF - Africa 55
OC - Oceania 31
Totale 9.273
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.211
PL - Polonia 1.174
RU - Federazione Russa 831
SG - Singapore 428
CN - Cina 354
HK - Hong Kong 282
IT - Italia 271
SE - Svezia 234
IE - Irlanda 193
VN - Vietnam 155
BR - Brasile 149
KR - Corea 135
DE - Germania 115
FI - Finlandia 84
FR - Francia 77
UA - Ucraina 73
IN - India 59
GB - Regno Unito 52
BD - Bangladesh 33
CH - Svizzera 32
AU - Australia 30
JO - Giordania 29
TR - Turchia 23
CA - Canada 18
ID - Indonesia 15
JP - Giappone 13
EC - Ecuador 12
AR - Argentina 11
CI - Costa d'Avorio 11
IQ - Iraq 10
BE - Belgio 9
MX - Messico 9
NL - Olanda 9
ZA - Sudafrica 9
NG - Nigeria 8
ES - Italia 6
MA - Marocco 6
AE - Emirati Arabi Uniti 5
PH - Filippine 5
PK - Pakistan 5
SA - Arabia Saudita 5
DZ - Algeria 4
IL - Israele 4
KE - Kenya 4
PY - Paraguay 4
AZ - Azerbaigian 3
CO - Colombia 3
EG - Egitto 3
ET - Etiopia 3
NI - Nicaragua 3
AL - Albania 2
AT - Austria 2
BH - Bahrain 2
CL - Cile 2
HN - Honduras 2
KZ - Kazakistan 2
LB - Libano 2
LK - Sri Lanka 2
LT - Lituania 2
MY - Malesia 2
NP - Nepal 2
PA - Panama 2
SN - Senegal 2
TH - Thailandia 2
TN - Tunisia 2
UY - Uruguay 2
BJ - Benin 1
BO - Bolivia 1
BY - Bielorussia 1
CM - Camerun 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
GT - Guatemala 1
HU - Ungheria 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 9.273
Salva come PNG Salva come JPEG
Città #
Warsaw 1.173
Santa Clara 924
Fairfield 429
Ashburn 388
Singapore 290
Hong Kong 247
Chandler 232
Dublin 192
Seattle 174
Woodbridge 168
Houston 161
Cambridge 160
Wilmington 145
Seoul 132
Jacksonville 126
Beijing 95
San Jose 92
Ann Arbor 83
Lawrence 59
Altamura 57
Los Angeles 53
New York 52
Buffalo 48
Hefei 48
Princeton 47
Ho Chi Minh City 45
Lauterbourg 44
Boston 42
Moscow 41
Hanoi 33
Mumbai 33
Council Bluffs 32
Bern 31
Boardman 31
San Diego 31
Helsinki 30
The Dalles 30
Melbourne 29
Florence 26
Dallas 23
Munich 21
Medford 19
Shanghai 18
Izmir 16
São Paulo 16
Phoenix 15
Bremen 14
Jakarta 14
Dong Ket 13
Orem 13
Salerno 13
Tokyo 12
Turku 12
Abidjan 11
Andover 11
Kent 11
Da Nang 10
Frankfurt am Main 10
London 10
Milan 10
Paris 10
Falls Church 9
Haiphong 9
Naples 9
Norwalk 9
Rome 9
Brussels 8
Chicago 8
Clifton 8
Abuja 7
Atlanta 7
Brooklyn 7
Guayaquil 7
North Bergen 7
Redondo Beach 7
Toronto 7
Pune 6
Redwood City 6
Stockholm 6
Abu Dhabi 5
Chennai 5
Denver 5
Thái Bình 5
Amsterdam 4
Bologna 4
Brasília 4
Cagliari 4
Cape Town 4
Hangzhou 4
Hillsboro 4
Manchester 4
Nairobi 4
Newark 4
Pisa 4
Rio de Janeiro 4
Sétif 4
Treviso 4
West Jordan 4
Addis Ababa 3
Baku 3
Totale 6.577
Salva come PNG Salva come JPEG
Nome #
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 380
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis:an international study. 347
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 330
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 330
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 321
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis 317
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. 310
Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. 302
Thrombocytosis and leukocytosis interactions in vascular complications of essential thrombocythemia 295
Nuovi target terapeutici nelle malattie mieloproliferativa croniche Ph negative 274
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. 258
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. 207
Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. 206
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. 206
A multidisciplinary case report of multiple myeloma with renal and cardiac involvement: a look beyond amyloidosis 194
Inconsistencies in the association between the JAL2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases 192
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. 191
Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients 185
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. 181
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience 179
Chemotherapy-related nail toxicity 175
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 174
Leukocytosis and risk stratification assessment in essential thrombocythemia. 168
Thrombosis in primary myelofibrosis: incidence and risk factors. 168
Treatment options for essential thrombocythemia and polycythemia vera 163
Aggressive Disease Course of Multiple Myeloma with Concomitant ALK-Negative Anaplastic Large Cell Lymphoma: A Case Report with an Unusual Presentation 162
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network 161
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 159
Ventricular tachyarrhythmias and sudden cardiac death in light-chain amyloidosis: a clash of cardio-toxicities? 159
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis 158
Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. 154
Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. 151
Risk of second cancers in chronic myeloproliferative neoplasms. 150
Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. 147
Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study 144
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. 142
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. 141
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. 137
Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study 133
JAK2V617F allele burden and thrombosis: a direct comparison in Essential Thrombocythemia and Polycythemia Vera 132
No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia. 131
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. 129
Mastocitosi: approccio multidisciplinare a una patologia misconoscciuta 128
Risk of second cancers in chronic myeloproliferative neoplasms 125
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis 123
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. 114
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. 106
Percorsi diagnostici-terapeutici per le neoplasie mieloproliferative nella AOU Careggi 96
Carfilzomib‐Induced Thrombotic Microangiopathy—Two Case Reports 80
Combined Minimal Residual Disease Evaluation in Bone Marrow and Apheresis Samples in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Improves Outcome Prediction 9
MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM. 4
Totale 9.328
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.535
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.535
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202195 0 0 0 0 0 0 0 0 0 0 41 54
2021/2022367 7 58 22 9 11 18 22 20 13 13 76 98
2022/2023974 88 174 47 98 76 157 116 58 89 7 28 36
2023/2024371 16 43 53 18 24 78 8 61 9 20 32 9
2024/20252.442 67 231 169 343 749 362 29 165 119 56 75 77
2025/20262.068 266 308 175 135 265 110 274 93 142 175 125 0
Totale 9.328